CCL2 and glioblastoma: One example is an anti-CCL2 (or anti-MCP1) antibody that is able to extend modestly, albeit significantly, the survival of GBM tumor-bearing mice in which a diminution in the number of TAMs in the tumor microenvironment has been observed [103].